Document ID: chunk:federal_register_of_legislation:F2024C01281:clause:1ab_293
Version: federal_register_of_legislation:F2024C01281
Segment Type: clause
Provision Reference: sch 1AB cl 293
Character Range: 828849–832542

293       Biosimilar Education and Electronic Prescribing                                                                                                      To fund the following:
                                                                                                                                                               (a) an organisation to develop information and educational materials and modules for clinicians, pharmacists and consumers to support the uptake of biosimilar medicines;
                                                                                                                                                               (b) an organisation to develop and deliver information and educational activities for health professionals, other health service providers and consumers to support the uptake of biosimilar medicines;
                                                                                                                                                               (c) the development of software to support the uptake of generic and biosimilar medicines;
                                                                                                                                                               (d) the enhancement of software to improve quality prescribing and enhance management of the availability of medicines, pharmacovigilance, safety reporting and compliance with the Pharmaceutical Benefits Scheme;
                                                                                                                                                               (e) the enhancement of software to support the safe management and supply of controlled drugs.
                                                                                                                                                               This objective also has the effect it would have if it were limited to measures:
                                                                                                                                                               (a) in connection with electronic communications; or
                                                                                                                                                               (b) providing, or incidental to the provision of, pharmaceutical benefits (within the meaning of paragraph 51(xxiiiA) of the Constitution); or
                                                                                                                                                               (c) giving effect to Australia's obligations under:
                                                                                                                                                               (i) the Convention on Psychotropic Substances, particularly Article 11; or
                                                                                                                                                               (ii) the International Covenant on Economic, Social and Cultural Rights, particularly Articles 2 and 12; or
                                                                                                                                                               (iii) the Single Convention on Narcotic Drugs (as amended), particularly Articles 2 and 4; or
                                                                                                                                                               (d) taken in the exercise of the executive power of the Commonwealth.